Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer.
Buzdar A, Hayes D, El-Khoudary A, Yan S, Lønning P, Lichinitser M, Gopal R, Falkson G, Pritchard K, Lipton A, Wolter K, Lee A, Fly K, Chew R, Alderdice M, Burke K, Eisenber P; Droloxifene 301 Study Group.
Buzdar A, et al.
Breast Cancer Res Treat. 2002 May;73(2):161-75. doi: 10.1023/a:1015229630260.
Breast Cancer Res Treat. 2002.
PMID: 12088118
Clinical Trial.